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1  | INTRODUC TION
The ongoing opioid epidemic has resulted in an increase in the num-
ber of deaths due to overdose with drugs of abuse. Between 2002 
and 2013, the rate of heroin- related overdose almost quadrupled, 
leading to a significant increase in donors classified as U.S. Public 
Health Service (PHS) increased risk of recent infection with HIV, 
hepatitis C, or hepatitis B.1,2 Donors with very recent intravenous 
drug use (IVDU) might have bloodborne infections not detected by 
serologic and nucleic acid testing (NAT) (ie, be in the window period) 
required of all PHS increased risk donors (IRD).
The Organ Procurement and Transplantation Network (OPTN)/
United Network for Organ Sharing (UNOS) Disease Transmission 
Advisory Committee (DTAC) receives reports of all potential donor 
disease transmission events with the goal of collecting information 
that can be used to improve OPTN/UNOS policy and educate the 
transplant community to promote patient safety related to disease 
transmission from donors to recipients. The purpose of this study is 
to analyze potential donor- derived hepatitis C virus (HCV) reported 
to the OPTN and to estimate the risk of transmission of HCV from 
donors with various risk factors for recent acquisition of HCV.
2  | MATERIAL S AND METHODS
All reports of potential donor- derived transmission events (PDDTEs) 
received and reviewed by the DTAC from January 2008 to December 
2016 were searched for HCV. The determination of whether or not 
donor- derived infection occurred was based on previously pub-
lished standard DTAC criteria.3-5 Each organ recipient was classified 
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The opioid epidemic has resulted in a potential increase in donors in the testing win-
dow period for hepatitis C virus (HCV). We analyzed HCV reports to the Disease 
Transmission Advisory Committee (DTAC) between 2008 and 2016 to estimate the 
risk	of	HCV	transmission.	In	15	of	95	(16%)	reports,	at	least	one	recipient	developed	
proven/probable donor- derived HCV resulting in 32 infected recipients. Seven trans-
missions occurred during the nucleic acid testing (NAT) window period; four occurred 
during serological window period. The other four transmission occurred due to 
human error (3) and false- negative serology (1). All seronegative- exposed liver and 
lung	recipients	contracted	HCV;	18/21	(86%)	kidney	and	3/4	(75%)	heart	recipients	
developed HCV. Four transmitting donors died of intravenous drug overdose, three 
in 2016 and one in 2012. Among donors with a history of intravenous drug use 
(IVDU), drug intoxication as a mechanism of death, or increased risk status, and nega-
tive screening HCV testing, the risk of transmission to a recipient was about 1 in 
1000. The overall risk of transmitting HCV from NAT- negative donors with IVDU is 
low and consistent with modeling data. This information may be helpful to clinicians 
counseling potential recipients offered these organs.
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as having proven, probable, possible, unlikely, or excluded donor- 
derived HCV. For all proven and probable instances of a donor trans-
mitting HCV to at least one recipient, the following information was 
collected: demographics, number of recipients exposed and number 
of organs infected, results of donor HCV serological testing and (if 
done) NAT testing, donor PHS increased risk designation, and time 
from admission to performance of NAT (if done).
In addition to donor screening test results, further test results 
including NAT testing performed at tissue banks (typically done after 
the organ transplants were completed) as well as testing done by 
the CDC as part of the case investigation was collected. Using this 
information, each proven or probable donor transmission event was 
classified as one of the following:
1. Serological window period
a. Donor screening serology nonreactive
b. NAT performed on donor specimen at tissue bank or as part of 
transmission investigation resulted reactive
2. NAT window period
a. Donor screening serology nonreactive
b. Donor screening NAT nonreactive
3. Human error
a. Positive HCV screening test on either blood vessels or donor 
was not properly communicated leading to HCV transmission
4. False negative serology
a. Initial donor serologic testing was negative, NAT screening 
was not performed, but repeat serology as part of investiga-
tion was positive
Donors from recipients with proven or probable donor- derived 
HCV were reviewed to determine if donor death was a result of ac-
tive injectable drug use. This information was obtained by specifically 
reviewing donor information collected by the Organ Procurement 
Organization as it is not a specific searchable OPTN data field.
Reports from cases that were not classified as proven or prob-
able were reviewed to determine the reason for filing the report. 
Categories included false- positive antibody (defined by negative on 
retest at CDC), false- positive NAT, infection not donor- derived, and 
other/unknown.
While OPTN data fields do not categorize donors as having 
active intravenous drug at time of death, fields do include “drug 
intoxication as a mechanism of death” although this field is not lim-
ited to drug intoxication due to injected drugs of abuse but includes 
other mechanisms of death unrelated to risk of HCV transmission 
such as acetaminophen overdose. In addition, the OPTN collects 
“history of intravenous drug use” but use may have occurred at any 
time in the donor’s life. OPTN data were used to determine the 
number of donors from 2008 to 2016 who were positive for ei-
ther/both “drug intoxication as a mechanism of death” or “history 
of intravenous drug use.” Further OPTN data were reviewed to 
determine which donors that transmitted HCV to at least one re-
cipient were positive for either of these data fields. We could then 
calculate the risk of donor- derived HCV for various risk factors 
using as a denominator characteristics recorded for all donors that 
would be available to clinicians offering organs to potential recip-
ients. These denominators included all donors during the study 
period with “drug intoxication as a mechanism of death” and “his-
tory of intravenous drug, either of those characteristics or both of 
those characteristics. Numerators were donors with those same 
characteristics with proven or probable transmission of hepatitis 
C to at least one recipient. The same analysis was conducted using 
all donors nationally classified as increased risk donors during the 
study period.
DTAC reviews information under confidential medical peer re-
view, and information was summarized to prevent recognition of an 
individual case or institution.
3  | RESULTS
Between January 2008 and December 2016, 2053 total PDDTE re-
ports	were	 reviewed	 by	 the	DTAC.	Of	 these	 reports,	 95	 involved	
HCV (Table 1). For 15 of these reports, at least one recipient de-
veloped proven or probable donor- derived HCV infection (Figure 1). 
Among the 36 HCV seronegative recipients of an organ from these 
donors,	 32	 (89%)	 acquired	 donor-	derived	 HCV	 infection.	 All	 sus-
ceptible lung and liver recipients developed donor- derived HCV 
infection.	Donor-	derived	HCV	infection	occurred	in	18/21(86%)	of	
susceptible	kidneys	and	3/4	(75%)	of	susceptible	heart	recipients.
In 80 reports, no recipient developed proven or probable donor- 
derived HCV. Nineteen of these reports were generated due to a 
false- positive serology, 15 due to a false- positive NAT, and 21 were 
a result of infection in the recipient which after analysis was deter-
mined not to be donor- derived. In 25 cases, reports were made for 
other reasons or due to a positive test in a recipient that was not likely 
donor- derived but information was insufficient to determine whether 
the test was a false- positive or true- positive. In most cases, this was 
due to an HCV- seropositive NAT- negative recipient, often reported 
years after transplant.
Eleven	 of	 the	 fifteen	 (73%)	 cases	 with	 proven	 or	 probable	 HCV	
transmission were due to window period infection (seven NAT window 
period and 4 serological window period) (Figure 1). Among donors who 
had screening NAT performed preprocurement, the time from hospital 
admission	to	blood	sample	drawn	for	NAT	ranged	from	13	to	96	hours.	
All four donors in the serological window period had a positive NAT test 
performed or resulted postprocurement (most commonly done as part 
of screening for tissue donation). In three of the other four cases, pre-
transplant HCV testing was not properly noted or communicated and 
organs were unintentionally transplanted into seronegative recipients. In 
one case, a screening serology resulted negative, but subsequent post-
procurement serological and NAT testing of stored donor specimens per-
formed at the CDC demonstrated this to be a false- negative test.
In all seven cases of NAT window period transmission, the donor 
was classified as a PHS IRD. Two of four serological window period 
donors were IRD. Reasons for increased risk status among these nine 
IRDs included IVDU (5), prison (2), sexual exposure (1), and lack of med-
ical history (1). The 11 window period donors were further reviewed to 
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see whether they qualified for the OPTN data fields “history of IVDU” 
and “drug intoxication” as mechanism of death; four of these donors 
were negative for both categories. A separate review of the charts of 
15 donors who transmitted HCV to at least one recipient was con-
ducted to determine how many died of active IVDU. Four of these 15 
donors died of active IVDU, one in 2012 and three in 2016 (Figure 2).
From	 January	 2008	 to	December	 2016,	 organs	 from	5294	or-
gans from donors with a history of IVDU, 5156 donors with drug 
intoxication as a mechanism of death, and 11 143 donors character-
ized as increased risk were procured. These data were used to esti-
mate the risk of HCV transmission from donors in these risk groups. 
Table 2 describes the risk of donor- derived HCV originating from 
donors with these risk factors.
4  | DISCUSSION
Among potential donors with risk factors for window period infec-
tion with HCV but negative screening tests, donor- derived infection 
remains rare. Donors with either drug intoxication as a mechanism 
of death or a history of IVDU had an approximately 1 in 1000 risk 
of transmitting HCV to at least one recipient. This risk is similar to 
that calculated using modeling techniques.6,7 A recent CDC publica-
tion	estimated	a	risk	of	HCV	donor	infection	of	about	1%	for	NAT-	
negative donors with IVDU in the 5 days prior to procurement.6 
A meta- analysis of studies describing incidence rates of HCV in 
various high- risk populations calculated risk of NAT window period 
transmission of 3.24 per 1000 donors with a history of IVDU.7 It is 
not surprising that this estimate is slightly higher than this report 
as most studies reviewed in the meta- analysis included recent (past 
1- 2 months) drug use rather than a history of ever using intravenous 
drugs. Further, the category of drug intoxication as a mechanism of 
death includes deaths unrelated to the risk of window period HCV 
infection (eg, suicide due to acetaminophen overdose).
All HCV- exposed pretransplant seronegative liver recipients did 
develop	HCV	 infection,	 but	3/21	 (14%)	 exposed	 kidney	 recipients	
and	1/4	(25%)	exposed	heart	recipients	did	not	develop	HCV	infec-
tion. This may be due to the presence of HCV in the liver but not in 
the blood early in infection.
The circumstance of greatest concern to clinicians for NAT win-
dow period infection with HCV is the donor who died from active 
IVDU. Clinicians are commonly faced with this situation given the 










Donor with drug 
intoxication as 
mechanism of death
Donor with history of 




2008 8 1 7 1 0 3/3
2009 10 2 8 1 1 2/2
2010 7 1 6 0 0 1/1
2011 11 3 8 2 1 4/4
2012 11 1 10 3 3 2/2
2013 11 0 11 2 1 0/0
2014 14 2 12 1 2 6/8
2015 6 1 5 0 0 3/3
2016 17 4 13 4 4 11/13
Total 95 15 80 14 12 32/36
aExcluded exposed recipients hepatitis C antibody- positive pretransplant. 
F IGURE  1 Characteristics of 15 
donors that transmitted hepatitis C to at 
least one recipient
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almost 10- fold increase in donors with a history of IVDU or drug 
intoxication as a mechanism of death from 2008 to 2016. Further, 
the number of PHS IRD has increased substantially.8
To provide optimal informed consent to patients offered these 
organs, clinicians need data on the risk of NAT window period 
HCV transmission, particularly from donors who die of active in-
travenous drug use. The data in this study provide some informa-
tion on the risk associated with donors with active IVDU—needle 
in the arm donors—at the time of procurement. First, an increased 
number of NAT window period transmissions was observed in 
2016 with three infected donors compared to only one during 
the preceding 8 years among donors with active IVDU at the time 
of hospitalization (as determined by reviewing individual donor 
charts). These numbers are small and may not reflect a trend, but 
as more donors with active IVDU at the time of death are used, it 
would be expected that an increase in window period HCV trans-
missions would occur. Second, while OPTN data do not specifi-
cally separate IVDU as the mechanism of death (as compared with 
other forms of drug intoxication), donors that meet both criteria 
may reflect a population more likely to have died from overdose 
with intravenous drugs. From 2008 to 2016, 2410 donors met the 
criteria of both a history of IVDU and drug intoxication. Among 
these donors, 3 transmitted HCV to at least one recipient sug-
gesting a risk of about 1/1000.
Since 2015, HCV NAT testing has been required of all poten-
tial organ donors. Licensed donor screening NAT tests have a win-
dow period (3- 5 days compared to 70 days for serological assay.).9 
Nonetheless, given that HCV may be intermittently detectable by 
NAT prior to the “ramp up phase” of rapid viral load increase, nonre-
active NAT assays could occur later than the generally reported NAT 
window period.10,11 In the current study, the median time between 
admission to the hospital and obtaining the specimen for NAT was 
41	hours	with	a	range	of	13-	96	hours.	Thus,	nonreactive	NAT	test-
ing outside of the reported window period was not found. Modeling 
data suggest that the risk of a negative NAT test in a recently in-
fected donor decays considerably after 5 days from exposure to 
HCV.6 Thus, ideally, NAT would be obtained as late in the process 
as possible, but practical considerations limit the feasibility of per-
forming NAT testing later in the evaluation period as results are most 
useful if available at the time of organ offer.
In 2013, PHS guidelines were revised to better identify potential 
donors at higher risk of window period infection with HIV, HCV, or 
hepatitis B.12 Based on cases described in this report, PHS increased 
criteria did identify all NAT window period transmissions, including 4 
NAT window period donors classified as PHS increased risk based on 
criteria other than IVDU. It is worth noting, however, that the vast 
majority of NAT- negative IRD are not in the window period and cannot 
transmit HCV virus.
TABLE  2 Risk of proven or probable donor transmission of hepatitis C by risk factor 2008- 2016
Increased risk 
donors History of IVDU Drug intoxication
IVDU and/or drug 
intoxication
IVDU and drug 
intoxication




5/5294	(0.09%) 6/5156	(0.12%) 7/8040	(0.08%) 3/2410	(0.12%)
IVDU, intravenous drug use.
F IGURE  2 Donors that transmitted 
hepatitis C with and without active 
intravenous drug use as a mechanism of 
death. p/p, proven or probable; IVDU, 
active intravenous drug use at time of 
death
p/p= proven or probable










P/P: no active IVDU at time of death
P/P: active IVDU at time of death
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This study has a number of limitations. The DTAC reporting sys-
tem for PDDTE is mandatory but passive, and donor- derived infec-
tions may have occurred that were not reported. This would result in 
our numbers underestimating the risk of window period transmission. 
Further adherence to policy requirements for follow- up testing of 
recipients of IRD organs has not been universally followed, possibly 
resulting in undiagnosed cases of transmission.13 As donor- derived 
infection with HCV is a relatively high profile event compared to 
other more routine or difficult to diagnose donor- derived infections, 
the number of unreported transmissions would be expected to be 
low. The use of screening NAT testing for all donors has only been 
required since 2015, although use was fairly common prior to that 
time. Universal NAT would be expected to prevent some transmis-
sion in later years that might diminish any temporal trend and result in 
an overestimation of the overall risk of HCV transmission during the 
study period. Changes in required testing combined with the opioid 
epidemic itself and local outbreaks of HCV among the IVDU pop-
ulation might alter the local risk of HCV transmission from a donor 
with a history of intravenous drug use and/or drug intoxication as 
a mechanism of death. Further limitations include the overall small 
number of donor- derived infections that occurred making it difficult 
to determine whether a trend of increased window period infec-
tions was occurring in 2016 or whether the increase was an anomaly. 
It should also be noted that cases from a previous investigation of 
three clusters of probable donor- derived hepatitis C are included in 
this paper.14 Finally, we did not have information on the precise time 
of the injection leading to fatal overdose, and substituted time from 
hospital admission to obtaining NAT. This would have the effect of 
underestimating the true window period associated with NAT testing.
As the number of organ offers received from potential donors 
with recent active IVDU continues to increase, categorically declin-
ing to use these organs due to fear of window period HCV infection 
will significantly limit the number of donors available for recipients 
listed at a particular center. In order to counsel potential recipi-
ents, clinicians need more information to help them communicate 
to potential recipients the risk of window period HCV infection and 
subsequent risk of recipient infection. Based on reports to OPTN/
UNOS, this study demonstrates a risk of about 1/1000 among do-
nors with a history of IVDU, drug intoxication as a mechanism, or a 
combination of those behaviors. Based on previous modeling stud-
ies and the reporting limitations discussed above, the true risk of 
window	period	HCV	infection	is	likely	<1%.	This	low	risk	should	be	
considered in the context of highly effective hepatitis C treatments 
that can be administered after transplantation. While more cases of 
donor- derived HCV from window period active IVDU donors were 
observed in 2016 compared to previous years, the absolute risk ap-
pears to be low. A multicenter collaborative study conducted among 
centers that use significant numbers of active IVDU donors with 
careful recipient follow- up would provide further data regarding the 
true risk associated with these donors. Given the mismatch between 
organ availability and need, it is critical that information is available 
to allow this growing proportion of potential organ donors to be op-
timally but safely used.
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